Benitec Biopharma Price To Sales vs. Total Debt
| BNTC Stock | USD 10.09 0.36 3.70% |
Benitec Biopharma Price To Sales Ratio |
|
For Benitec Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Benitec Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Benitec Biopharma Ltd utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Benitec Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Benitec Biopharma Ltd over time as well as its relative position and ranking within its peers.
Benitec |
Benitec Biopharma's Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share 0.003 | Quarterly Revenue Growth 0.125 | Return On Assets (0.50) | Return On Equity (0.92) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Benitec Biopharma Total Debt vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Benitec Biopharma's current stock value. Our valuation model uses many indicators to compare Benitec Biopharma value to that of its competitors to determine the firm's financial worth. Benitec Biopharma Ltd is number one stock in price to sales category among its peers. It is rated below average in total debt category among its peers making up about 102.52 of Total Debt per Price To Sales. At present, Benitec Biopharma's Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Benitec Biopharma's earnings, one of the primary drivers of an investment's value.Benitec Total Debt vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Benitec Biopharma |
| = | 2,770 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Benitec Biopharma |
| = | 284 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Benitec Total Debt vs Competition
Benitec Biopharma Ltd is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 196.76 Million. Benitec Biopharma adds roughly 284,000 in total debt claiming only tiny portion of equities under Health Care industry.
Benitec Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Benitec Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Benitec Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Benitec Biopharma's change in net profit over the period of time. It can combine multiple indicators of Benitec Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -892 K | -847.4 K | |
| Operating Income | -22.5 M | -21.4 M | |
| Income Before Tax | -22.4 M | -21.3 M | |
| Total Other Income Expense Net | 120 K | 126 K | |
| Net Loss | -21.8 M | -20.7 M | |
| Income Tax Expense | -619 K | -650 K | |
| Net Loss | -21.8 M | -20.7 M | |
| Net Loss | -17.6 M | -18.5 M | |
| Interest Income | 5.4 K | 5.1 K | |
| Non Operating Income Net Other | -49.5 K | -47 K | |
| Net Interest Income | 904 K | 949.2 K | |
| Change To Netincome | 409.5 K | 591.5 K | |
| Net Loss | (5.36) | (5.63) | |
| Income Quality | 0.89 | 1.28 | |
| Net Income Per E B T | 0.88 | 0.79 |
Benitec Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Benitec Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Benitec Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Benitec Biopharma's important profitability drivers and their relationship over time.
Use Benitec Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Benitec Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Benitec Biopharma will appreciate offsetting losses from the drop in the long position's value.Benitec Biopharma Pair Trading
Benitec Biopharma Ltd Pair Trading Analysis
The ability to find closely correlated positions to Benitec Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Benitec Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Benitec Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Benitec Biopharma Ltd to buy it.
The correlation of Benitec Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Benitec Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Benitec Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Benitec Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Benitec Biopharma position
In addition to having Benitec Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
To fully project Benitec Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Benitec Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Benitec Biopharma's income statement, its balance sheet, and the statement of cash flows.